Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line. Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Eli Lilly currently markets two GLP-1 receptor agonist medications: Tirzepatide, sold under the brand names Mounjaro and Zepbound, and Dulaglutide, sold as Trulicity. Recently, BofA’s four-star ...